吉西他滨联合顺铂治疗晚期膀胱癌的临床观察  

The efficacy and toxicity of gemcitabine combined with cisplatin for advanced bladder cancer

作　　者：陈勇[1] 周宇红[1] 仓晨[2] 王志明[1] 刘天舒[1] 金文[1] 庄荣源[1] 宋燕[1] 李倩[1] 

机构地区：[1]复旦大学附属中山医院肿瘤内科,上海200032 [2]复旦大学附属中山医院泌尿外科,200032

出　　处：《临床肿瘤学杂志》2011年第5期441-443,共3页Chinese Clinical Oncology

摘　　要：目的评价吉西他滨联合顺铂化疗方案在晚期膀胱癌中的疗效及安全性。方法 33例接受一线化疗的晚期膀胱癌,予吉西他滨1000mg/m2于第1、8天静脉滴注,顺铂25 mg/m2第1~3天静脉滴注,3周重复,每3个月评价客观疗效和毒副反应,并随访无进展生存期（PFS）及总生存时间。结果 33例患者中完全缓解9例,部分缓解7例,有效率为48.5%;中位无进展生存时间为11个月,中位生存时间18个月,1年生存率58.0%。3~4级白细胞减少9例（27.3%）,3~4级粒细胞减少6例（18.2%）,3~4级血小板减少9例（27.3%）,3~4级恶心呕吐6例（18.2%）。结论吉西他滨联合顺铂3周方案治疗晚期膀胱癌安全、有效。Objective To assess the efficacy and toxicity of gemcitabine combined with cisplatin as the first-line treatment for advanced bladder cancer.Methods Thirty three patients with advanced bladder cancer were treated with gemcitabine 1000 mg/m2on d1,d8 and cisplatin 25 mg/m2 on d1-d3.Cycles were repeated every 3 weeks.Thirty three patients were evaluated by radiologic objective response（OR）,progression-free survival（PFS） and overall survival time were recorded.Results Of 33 assessable patients,the overall response rate was 48.5%,including 9 complete response and 7 partial response patients.Median time of progression-free survival was 11 months,median survival time was 18 months,and 1-year survival rate was 58.0%.The main toxic response was myleosuppression,nausea and vomiting.Conclusion Three-week regimen of gemcitabine combined with cisplatin is safe and effective for patients with advanced bladder cancer.

关 键 词：晚期膀胱癌 吉西他滨 顺铂 疗效 毒性 化学治疗 

分 类 号：R737.14[医药卫生—肿瘤]